Eli Lilly to Spend $850 Million on U.S. Manufacturing

Diabetes is a key focus for the Big Pharma company.

Pharmaceutical giant Eli Lilly has announced plans to invest $850 million in its U.S. operations in 2017, with diabetes a particular focus. The plans were revealed during a special event at the Lilly Technology Center at Indianapolis, where the company also called for “a more favorable tax environment” to support further boosts to domestic manufacturing.

“Our future at Lilly is bright, as we're on a path to launch 20 new products in a ten-year time frame,” said President and CEO David Ricks. “As we have for our entire 140-year history, we continue to see Indiana and the United States as attractive places to research and make the medicines that we sell around the world.”

The investment covers research laboratories, manufacturing sites and general and administrative areas. Among the highlights are a $85 million expansion of Lilly’s Trulicity (dulaglutide) device assembly operations, on top of the official dedication during the event of a $140 million insulin cartridge production facility.

Lilly has spent over $1.1 billion over the past five years on the manufacture of diabetes products. There have been upgrades to existing facilities, new capacities and new capabilities based on its own pipeline and the rapid growth of the condition, which now affects about 30 million people in the U.S. and over 400 million worldwide. The company has produced insulin for some 90 years.

Other parts of the investment will be focused on pipeline products in therapies including cancer and pain, as well as other unmet medical needs. According to Ricks, both existing and newly initiated projects will be funded, including some in Indianapolis

Between 2012 and 2016, Lilly increased its U.S manufacturing workforce by more than 1,000 employees to 6,000, of which 400 were added in Indianapolis. During that time, the investment has sustained an average of 500 construction jobs and nearly 1,000 at peak. This will continue with the ongoing work at the Lilly Technology Center.


Guy Tiene

Guy supports the success of life science organizations by identifying synergies across research, content, marketing and communications resources to drive value for clients. With over 30 years of education and marketing experience and 18 years in the life sciences alone, Guy leads our editorial standards for client content, Pharma’s Almanac and Nice Insight research-based industry content as well as external communications for clients. Having served as head of global marketing and communications for a CMO, he also brings critical insight and guidance to all communications. Guy holds a Masters degree from Columbia University.